Patent SG-11201801401U-A (SG)
Title: A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
Inventor: SHINOMIYA KENJI
IPC: C07K16/18
Filed: 2018-01-31
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 09 August 2018 (09.08.2018) WIP0 I PCT ~~ll~~~~~~~~ 011101010VIIIOH olo olo mil mom Kuno ow (10) International Publication Number WO 2018/143266 Al W O 20 18/ 143 266 Al (51) International Patent Classification: C07K 16/18 (2006.01) A61K 39/00 (2006.01) (21) International Application Number: PCT/JP2018/003193 (22) International Filing Date: 31 January 2018 (31.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 10201700775Y 31 January 2017 (31.01.2017) SG 10201705954V 20 July 2017 (20.07.2017) SG (71) Applicants: CHUGAI SEIYAKU KABUSHIKI KAISHA [JP/JP]; 5-1, Ukima 5-chome, Kita-ku, Tokyo, 1158543 (JP). F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, Basel, CH4070 (CH). (72) Inventors: SHINOMIYA, Kenji; c/o CHUGAI SEIYAKU KABUSHIKI KAISHA, 1-1, Nihon- bashi-Muromachi 2-chome, Chuo-ku, Tokyo, 1038324 (JP). YONEYAMA, Koichiro; c/o CHUGAI SEIYAKU KABUSHIKI KAISHA, 1-1, Nihonbashi-Muromachi 2-chome, Chuo-ku, Tokyo, 1038324 (JP). SHIBA- HARA, Norihito; c/o CHUGAI SEIYAKU KABUSHIKI KAISHA, 135, Komakado 1-chome, Gotemba-shi, Shizuo- ka, 4128513 (JP). TSUBOI, Yoshinori; c/o CHUGAI SEIYAKU KABUSHIKI KAISHA, 135, Komakado 1- chome, Gotemba-shi, Shizuoka, 4128513 (JP). FUKUZA- WA, Taku; c/o Chugai Pharmabody Research Pte. Ltd., 3, Biopolis Drive, #07-11 to 16 Synapse, 138623 (SG). HARAYA, Kenta; c/o Chugai Pharmabody Research Pte. Ltd., 3, Biopolis Drive, #07-11 to 16 Synapse, 138623 (SG). SAMPEI, Zenjiro; c/o Chugai Pharmabody Research Pte. Ltd., 3, Biopolis Drive, #07-11 to 16 Synapse, 138623 (SG). BOGMAN, Katrijn; c/o F. Hoffmann-La Roche AG, Gren- zacherstrasse 124, Basel, CH4070 (CH). CHAROIN, Jean Eric; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, Basel, CH4070 (CH). (74) Agent: HARUNA, Masao et al.; Kantetsu Tsukuba Bldg. 6F, 1-1-1, Oroshi-machi, Tsuchiura-shi, Ibaraki, 3000847 (JP). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (54) Title: A PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OR PREVENTION OF A CS-RELATED DISEASE AND A METHOD FOR TREATING OR PREVENTING A CS-RELATED DISEASE (57) : The present invention relates to pharmaceutical compositions for use in the treatment or prevention of a CS-related disease and methods for treating or preventing a CS-related disease. The present invention further relates to dosages and administrations of anti-CS antibody or pharmaceutical compositions containing the anti-CS antibody.